Shire has published findings from a head-to-head clinical study comparing the efficacy of two non-calcium based phosphate binders, Fosrenol and Genzyme’s Renagel in chronic kidney disease (CKD) patients on haemodialysis.
The results of the study showed a statistically larger reduction in serum phosphorus within the group, suggesting that Fosrenol may offer greater serum phosphorus reduction in CKD patients on haemodialysis.
Go deeper with GlobalData
In this 12-week crossover study, patients were randomized to receive either Fosrenol or Renagel for four weeks, and then switched to the alternative phosphate binder for the same period.
Trial lead investigator Professor Stuart Sprague said that the findings suggest that over four weeks of treatment, Fosrenol may be a more effective binder of phosphate.
“Further research is now required to evaluate whether the trends observed in this crossover study are continued in the long term,” said Sprague.
The study’s primary endpoint, change in serum phosphorus from baseline to end of treatment, was evaluated using several statistical analyses.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
